Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned an average recommendation of "Buy" from the nine brokerages that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $13.97.
VYGR has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the stock an "overweight" rating in a report on Wednesday, March 12th. Canaccord Genuity Group cut their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th.
Read Our Latest Analysis on VYGR
Insider Transactions at Voyager Therapeutics
In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.53% of the company's stock.
Institutional Trading of Voyager Therapeutics
Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock valued at $6,316,000 after acquiring an additional 6,740 shares during the period. Barclays PLC boosted its holdings in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company's stock worth $612,000 after buying an additional 37,398 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock valued at $223,000 after buying an additional 7,573 shares during the period. Rhumbline Advisers increased its holdings in Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after buying an additional 2,354 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Voyager Therapeutics by 8.1% in the fourth quarter. American Century Companies Inc. now owns 122,726 shares of the company's stock worth $696,000 after acquiring an additional 9,190 shares during the period. Hedge funds and other institutional investors own 48.03% of the company's stock.
Voyager Therapeutics Price Performance
Voyager Therapeutics stock traded up $0.01 during trading hours on Monday, reaching $3.50. The stock had a trading volume of 125,377 shares, compared to its average volume of 452,799. The company has a market cap of $193.00 million, a price-to-earnings ratio of 4.92 and a beta of 1.02. The business's 50 day moving average price is $3.68 and its 200-day moving average price is $5.24. Voyager Therapeutics has a 52 week low of $2.75 and a 52 week high of $9.55.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the firm earned $1.25 EPS. On average, sell-side analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.
Voyager Therapeutics Company Profile
(
Get Free ReportVoyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Further Reading
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
